U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. For Industry
  3. FDA User Fee Programs
  4. Prescription Drug User Fee Amendments
  5. Condition-Specific Meeting Reports and Other Information Related to Patients' Experience
  1. Prescription Drug User Fee Amendments

Condition-Specific Meeting Reports and Other Information Related to Patients' Experience

This webpage provides links to certain publicly available external reports and resources relating to patient experience data. The patient community, patient advocates, researchers, drug developers, and federal agencies may find these materials useful. For specific questions related to a report or resource, FDA recommends reaching out to the point of contact listed on the cover page of the report.

This webpage hosts an alphabetical listing of condition-specific meeting reports and other information related to patients’ experience. These meetings include FDA-led Patient-Focused Drug Development (PFDD) meetings, Externally-led PFDD meetings, and Patient Listening Sessions. Other information includes proposed draft guidance relating to patient experience data, natural history studies, or other condition-specific background on condition and discussion of unmet medical need.

FDA’s Office of Patient Affairs is responsible for managing the Agency’s Patient Listening Session program. While conditions for which there were Patient Listening Sessions conducted are listed individually on this page, the link will direct you to the Patient Listening Session page where you will be able to see all the Patient Listening Session Summaries posted by the Office of Patient Affairs.

For more information regarding what types of resources may be included on this webpage, how to submit a publicly available website link to FDA, and other general questions, please review our Frequently Asked Questions. For EL-PFDD meeting summary reports, we request that links include a cover page or similar opening statement as part of their report or resource to provide information about the authors, funding, and related information.

Please note that although FDA reviews the materials that link to external pages before posting them to ensure that the materials are within the scope of the webpage, FDA does not assess their scientific merit or compliance with regulatory requirements. Our decision to post links to these materials does not reflect an endorsement of their authors, sponsors, or content.

 

Disease or Condition (alphabetical)

Type of Meeting

Resource(s)

Meeting Date

Thalassemia

EL-PFDD Meeting
Host: Cooley’s Anemia Foundation

Report Unavailable July 7, 2017
Neurofibromatosis Type 1 (NF1)/ Cutaneous Neurofibroma (cNF)

Patient Listening Session

Patient Listening Session Summary May 21, 2024
KCNT1-Related Epilepsy

Patient Listening Session

Patient Listening Session Summary April 22, 2024
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)

Patient Listening Session

Patient Listening Session Summary January 17, 2024
Attention-Deficit/Hyperactivity Disorder (ADHD)

Patient Listening Session

Patient Listening Session Summary March 15, 22, and 29, 2024
Long QT Syndrome (LQTS)

EL-PFDD Meeting
Host: SADS Foundation

Report pending June 11, 2024
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

EL-PFDD Meeting
Host: SADS Foundation

Report pending June 11, 2024
Adult Dermatomyositis (DM)

EL-PFDD Meeting
Host: Myositis Support and Understanding

Report pending June 7, 2024
Peroxisomal Disorders: Zellweger spectrum disorder (ZSD), acyl-CoA oxidase 1 deficiency (ACOX1), D-bifunctional protein deficiency (DPBD), and 2-methylacyl-CoA racemase deficiency (AMACR)

EL-PFDD Meeting
Host: The Global Foundation for Peroxisomal Disorders (GFPD)

Report pending May 28, 2024
Rare, Autoimmune Peripheral Neuropathies: Guillain-Barre Syndrome (GBS), Multifocal Motor Neuropathy (MMN), and Anti-myeline-associated glycoprotein (Anti-MAG) neuropathy

EL-PFDD Meeting
Host: GBS|CIDP Foundation International

Report pending May 16, 2024
Idiopathic Hypersomnia (IH)

EL-PFDD Meeting
Host: Sleep Consortium

Report pending April 11, 2024
Congenital Cytomegalovirus Infection (cCMV)

Patient Listening Session

Patient Listening Session Summary April 4, 2024
Pelizaeus Merzbacher Disease (PMD)

Patient Listening Session

Patient Listening Session Summary August 22, 2023
Hypoparathyroidism

EL-PFDD Meeting
Host: HypoPARAthyroidism Association

Report pending March 5, 2024
Dry Age-Related Macular Degeneration (Dry AMD)

EL-PFDD Meeting
Host: Foundation Fighting Blindness

Report pending March 1, 2024
Pediatric Low-Grade Glioma (pLGG)

EL-PFDD Meeting
Host: Pediatric Brain Tumor Foundation

Meeting Report February 23, 2024
GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases)

EL-PFDD Meeting
Host: National Tay-Sachs & Allied Diseases Association (NTSAD)

Meeting Report February 15, 2024
Immune Thrombotic Thrombocytopenic Purpura (iTTP)

EL-PFDD Meeting
Host: The Ree Wyn Foundation

Report pending January 26, 2024
Pyruvate Dehydrogenase Complex Deficiency (PDCD) Patient Listening Session Patient Listening Session Summary September 8, 2023
Atypical Hemolytic Uremic Syndrome (aHUS) Patient Listening Session Patient Listening Session Summary September 21, 2023
Epidermolysis Bullosa (EB) EL-PFDD Meeting
Host: Dystrophic Epidermolysis Bullosa Research Association of America (Debra of America)
Meeting April 6, 2018
Spinal Cord Injury (SCI) Patient Listening Session Patient Listening Session Summary April 24, 2023
C. difficile Infections Patient Listening Session Patient Listening Session Summary March 10, 2023
Kidney Xenotransplantation EL-PFDD Meeting
Host: National Kidney Foundation
Report pending November 9, 2023
Polycystic Ovary Syndrome (PCOS) EL-PFDD Meeting
Host: PCOS Challenge: The National Polycystic Ovary Syndrome Association
Report pending November 3, 2023
Hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility spectrum disorders (HSD) EL-PFDD Meeting
Host: The Ehlers-Danlos Society
Report pending October 31, 2023
Classical Homocystinuria (HCU) EL-PFDD Meeting
Host: HCU Network America
Report pending October 27, 2023
STXBP1 EL-PFDD Meeting
Host: STXBP1 Foundation
Report pending October 20, 2023
Low-Grade Serous Ovarian Cancer (LGSOC) EL-PFDD Meeting
Host: STAAR Ovarian Cancer Foundation
Meeting Report October 13, 2023
Cystic Fibrosis (CF) EL-PFDD Meeting
Host: Cystic Fibrosis Research Institute
Meeting Report October 29, 2018
Spinocerebellar Ataxia Type 3 (SCA3) Patient Listening Session Patient Listening Session Summary September 22, 2023
Developmental and Epileptic Encephalopathy (DEE) EL-PFDD Meeting
Host: Lennox-Gastaut Syndrome Foundation
Meeting November 1, 2019
Cyclin-dependent kinase-like 5 deficiency disorder (CDKL5/CDD) EL-PFDD Meeting
Host: Loulou Foundation and the International Foundation for CDKL5 Research (IFCR)
Meeting Report November 1, 2019
Autosomal Recessive Polycystic Kidney Disease (ARPKD)

EL-PFDD Meeting
Host: PKD Foundation

Meeting Report August 29, 2023
Carcinoid Syndrome

Patient Listening Session

Patient Listening Session Summary April 27, 2023
Canavan Disease

Patient Listening Session

Patient Listening Session Summary March 21, 2023
Post-finasteride Syndrome (PFS)

Patient Listening Session

Patient Listening Session Summary June 2, 2023
Prader-Willi Syndrome (PWS)

EL-PFDD Meeting
Host: PWSA|USA

Meeting Report June 23, 2023
Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D)

EL-PFDD Meeting
Host: SADS Foundation

Meeting Report June 20, 2023
Recurrent Clostridium difficile Infections (rCDI)

Patient Listening Session

Patient Listening Session Summary March 10, 2023
Sickle Cell Disease

Patient Listening Session

Patient Listening Session Summary May 5, 2023
Pulmonary Alveola Proteinosis (PAP)

Patient Listening Session

Patient Listening Session Summary July 8, 2020
Bronchopulmonary Dysplasia (BPD)

Patient Listening Session

Patient Listening Session Summary March 20, 2023
Juvenile Idiopathic Arthritis (JIA)

EL-PFDD Meeting

Host: The Arthritis Foundation and the Childhood Arthritis and Rheumatology Research Alliance (CARRA)

Meeting Report April 2, 2018
Long COVID FDA-led PFDD Meeting April 25, 2023

Congenital Disorders of Glycosylation (CDG)

Patient Listening Session

Patient Listening Session Summary

January 30, 2023

Juvenile Huntington’s Disease (JHD)

Patient Listening Session

Patient Listening Session Summary

February 10, 2023

Pouchitis after a total colectomy and ideal pouch anal anastomosis (IPAA) surgery

Patient Listening Session

Patient Listening Session Summary

January 14, 2023

SYNGAP1

EL-PFDD Meeting

Host: SYNGAP1 Foundation

Meeting Report

November 19, 2020

Pre-Diagnosis Genetic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Degeneration (FTD)

Patient Listening Session

Patient Listening Session Summary

January 12, 2023

Proteus Syndrome

Patient Listening Session

Patient Listening Session Summary

December 1, 2022

Stargardt Disease (STGD1)

Patient Listening Session

Patient Listening Session Summary

June 24, 2022

Recurrent Respiratory Papillomatosis (RRP)

Patient Listening Session

Patient Listening Session Summary

October 27, 2022

Wiskott-Aldrich Syndrome (WAS) and X-Linked Thrombocytopenia (XLT)

EL-PFDD Meeting
Host: Wiskott-Aldrich Foundation

Meeting Report

February 3, 2023

Autoimmune Hepatitis (AIH) 

EL-PFDD Meeting
Host: Autoimmune Hepatitis Association

Meeting

January 27, 2023

Pemphigus and Pemphigoid

EL-PFDD Meeting
Host: International Pemphigus and Pemphigoid Foundation

Meeting Report

January 25, 2023

Cerebral Creatine Deficiency Syndromes (CCDS): L-arginine:glycine amidinotransferase (AGAT) deficiency, guanidinoacetate methyltransferase (GAMT) deficiency, and creatine transporter deficiency (CTD)

EL-PFDD Meeting
Host: Association for Creatine Deficiencies

Meeting Report

January 24, 2023

Narcolepsy and Idiopathic Hypersomnia (IH)

Patient Listening Session

Patient Listening Session Summary

August 8, 2022

Hypophosphatasia (HPP)

EL-PFDD Meeting
Host: Soft Bones, Inc., The US
Hypophosphatasia Foundation

Meeting Report

November 15, 2022

GM1 gangliosidosis

EL-PFDD Meeting
Host: Cure GM1 Foundation

Meeting Report

October 14, 2022

Metachromatic Leukodystrophy (MLD)

EL-PFDD Meeting
Host: Cure MLD, The Calliope Joy Foundation, MLD Foundation, The United Leukodystrophy Foundation, and the Global Leukodystrophy Initiative

Meeting Report

October 21, 2022

Schizophrenia

EL-PFDD Meeting
Host: The American Foundation for Suicide Prevention, Mental Health America, the National Alliance on Mental Illness (NAMI), the National Council for Mental Wellbeing, and Schizophrenia and Psychosis Action Alliance (S&PAA)

Meeting Report

November 2, 2022

Phelan-McDermid Syndrome (PMS)

EL-PFDD Meeting
Host: CureSHANK

Meeting Report

November 8, 2022

Kennedy’s Disease (KD)/ Spinal and bulbar muscular atrophy (SBMA)

EL-PFDD Meeting
Host: Kennedy’s Disease Association

Meeting Report

November 9, 2022

Short Bowel Syndrome (SBS)

Patient Listening Session

Patient Listening Session Summary

July 19, 2022

Huntington’s Disease (HD) Pre-Symptomatic Population

Patient Listening Session

Patient Listening Session Summary

July 25, 2022

Spinal Muscular Atrophy (SMA)

Patient Listening Session

Patient Listening Session Summary

August 4, 2022

Alstrom Syndrome (AS)

EL-PFDD Meeting

Host: Alstrom International

Meeting Report

September 22, 2022

Reducing Cardiac Late Effects in Pediatric Cancer Survivors

EL-PFDD Meeting

Host: Children’s Cancer Cause

Meeting Report

September 15, 2022

Fabry Disease

EL-PFDD Meeting

Host: National Kidney Foundation and Fabry Support & Information Group

Report pending

September 19, 2022

Galactosemia

EL-PFDD Meeting

Host: National Organization for Rare Disorders (NORD)

Meeting Report

September 1, 2022

Limb-Girdle Muscular Dystrophies (LGMD)

EL-PFDD Meeting

Host: Coalition to Cure Calpain 3, CureLGMD2i, the Kurt+Peter Foundation, the LGMD2D Foundation, the McColl-Lockwood Laboratory for Muscular Dystrophy Research, and the Speak Foundation

Meeting Report

September 23, 2022

Primary Biliary Cholangitis (PBC)

EL-PFDD Meeting
Host: Global Liver Institute

Meeting Report

February 4, 2022

Food Allergies

EL-PFDD Meeting
Host: Food Allergy Research and Education (FARE)

Meeting Report

September 9, 2021

Asthma

EL-PFDD Meeting
Host: Asthma and Allergy Foundation of America (AAFA)

Meeting Report

September 20, 2021

Myotubular and Centronuclear Myopathy (MTM/CNM)

EL-PFDD Meeting
Host: MTM-CNM Family Connection and Where There’s A Will There’s A Cure

Meeting

August 3, 2021

Rett Syndrome

EL-PFDD Meeting
Host: Rett Syndrome Research Trust (RSRT)

Meeting Report

March 11, 2022

Membranous Nephropathy (MN)

EL-PFDD Meeting
Host: National Kidney Foundation and NephCure Kidney International

Meeting Report

August 27, 2021

Cancer Cachexia

EL-PFDD Meeting
Host: Cancer Support Community

Meeting Report

November 2, 2021

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

EL-PFDD Meeting
Host: GBS|CIDP Foundation International

Meeting Report

March 25, 2022

Primary Hyperoxaluria (PH)

EL-PFDD Meeting
Host: The Oxalosis and Hyperoxaluria Foundation

Meeting Report

October 5, 2020

Post-Transplant Lymphoproliferative Disorder (PTLD)

EL-PFDD Meeting
Host: National Organization for Rare Disorders (NORD)

Meeting Report

May 4, 2022

Bronchiolitis Obliterans Syndrome (BOS)

EL-PFDD Meeting
Host: Lung Transplant Foundation

Meeting Report

June 22, 2022

Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)

EL-PFDD Meeting
Host: SSADH Association

Meeting Report

July 8, 2022

X-linked Retinitis Pigmentosa (XLRP)

EL-PFDD Meeting
Host: Fighting Blindness Foundation

Meeting Report

June 7, 2022

Congenital Muscular Dystrophy (CMD)

EL-PFDD Meeting
Host: Cure CMD

Report pending

July 1, 2022

Hermansky-Pudlak Syndrome (HPS)

EL-PFDD Meeting
Host: Hermansky-Pudlak Syndrome Network

Meeting Report

June 10, 2022

X-linked Adrenoleukodystrophy (ALD)

EL-PFDD Meeting
Host: ALD Connect

Meeting Report

July 22, 2022

Acromegaly

 

EL-PFDD Meeting
Host: Acromegaly Community, Inc.

Meeting Report

January 21, 2021

Acute Porphyrias

EL-PFDD Meeting
Host: American Porphyria Foundation

Meeting Report

March 1, 2017

Adrenomyeloneuropathy (AMN)

Patient Listening Session

Patient Listening Session Summary

May 7, 2021

Adult Dermatomyositis (DM)

Patient Listening Session

Patient Listening Session Summary

April 26, 2022

Adult Polyglucosan Body Disease (APBD)

Patient Listening Session

Patient Listening Session Summary

October 28, 2021

Alopecia Areata

FDA-led PFDD Meeting

September 11, 2017

Alpha-1 Antitrypsin Deficiency (AATD)

FDA-led PFDD Meeting

 

September 29, 2015

Alport Syndrome (AS)

EL-PFDD Meeting
Host: National Kidney Foundation and the Alport Syndrome Foundation

Meeting Report

August 3, 2018

Amyloidosis

EL-PFDD Meeting
Host: The Amyloidosis Research Consortium

Meeting Report

November 16, 2015

Amyotrophic Lateral Sclerosis (ALS)

N/A

IMPACT ALS Survey Report

N/A

Autism (ASD)

FDA-led PFDD Meeting

 

May 4, 2017

Barth Syndrome (BTHS)

EL-PFDD Meeting
Host: The Barth Syndrome Foundation

Meeting Report

July 18, 2018

Breast Cancer

FDA-led PFDD Meeting

 

April 2, 2015

Celiac Disease

Patient Listening Session

Patient Listening Session Summary

February 20, 2019

Cerebral Cavernous Malformation (CCM)

Patient Listening Session

Patient Listening Session Summary

November 6, 2019

Cerebrotendinous Xanthomatosis (CTX)

EL-PFDD Meeting
Host: United Leukodystrophy Foundation of America

Meeting Report

September 14, 2021

Chagas Disease

FDA-led PFDD Meeting

 

April 28, 2015

Charcot-Marie-Tooth and Inherited Neuropathies (CMT/IN)

EL-PFDD Meeting
Host: Hereditary Neuropathy Foundation

Meeting Report

September 28, 2018

Chemotherapy-Induced Hearing Loss

EL-PFDD Meeting
Host: Children’s Cause for Cancer Advocacy, Children’s Brain Tumor Foundation, Mattie Miracle Cancer Foundation, and Momcology

Meeting Report

September 13, 2018

Childhood Cerebral Adrenal Leukodystrophy (CCALD)

Patient Listening Session

Patient Listening Session Summary

November 13, 2019

Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS & ME)

FDA-led PFDD Meeting

 

April 25, 2013

Chronic Pain

FDA-led PFDD Meeting

 

July 9, 2018

Complement 3 Glomerulopathy (C3G)

EL-PFDD Meeting
Host: National Kidney Foundation

Meeting Report

August 4, 2017

Cystic Fibrosis (CF) – nonsense mutations

Patient Listening Session

Patient Listening Session Summary

July 15, 2021

Atopic Dermatitis (Eczema)

EL-PFDD Meeting
Host: Allergy and Asthma Network, Asthma and Allergy Foundation of America, Global Parents for Eczema Research, International Topical Steroid Awareness Network, and National Eczema Association

Meeting Report

September 23, 2019

Dravet Syndrome (DS)

EL-PFDD Meeting
Host: The Dravet Syndrome Foundation

Meeting Report

February 3, 2022

Fabry Disease

Patient Listening Session

Patient Listening Session Summary

December 4, 2018

Facioscapulohumeral Muscular Dystrophy (FSHD)

EL-PFDD Meeting
Host: FSHD Society

Meeting Report

June 29, 2020

Female Sexual Dysfunction (FSD)

FDA-led PFDD Meeting

 

October 27, 2014

Fibrodysplasia Ossificans Progressiva (FOP)

Patient Listening Session

Patient Listening Session Summary

May 29, 2019

Fibromyalgia

FDA-led PFDD Meeting

 

March 26, 2014

Focal Segmental Glomerulosclerosis (FSGS)

EL-PFDD Meeting
Host: National Kidney Foundation and NephCure Kidney International

Meeting Report

August 28, 2020

Fragile X Syndrome (FXS)

EL-PFDD Meeting
Host: National Fragile X Foundation

Meeting Report

March 3, 2021

Friedreich’s Ataxia (FA)

EL-PFDD Meeting
Host: Friedreich’s Ataxia Research Alliance

Meeting Report

June 2, 2017

Frontotemporal Degeneration (FTD)

EL-PFDD Meeting
Host: Association for Frontotemporal Degeneration (AFTD)

Meeting Report

March 5, 2021

Functional Gastrointestinal (GI) Disorders

FDA-led PFDD Meeting

 

May 11, 2015

Gastroparesis

Patient Listening Session

Patient Listening Session Summary

December 2, 2019

Gene Therapy as a Treatment Modality for Hemophilia

Patient Listening Session

Patient Listening Session Summary

October 23, 2018

Glycogen Storage Disease (GSD) Type 1 – Adult Patients

Patient Listening Session

Patient Listening Session Summary

March 18, 2021

Glycogen Storage Disease (GSD) Type 1 – Caregivers to Pediatric Patients

Patient Listening Session

Patient Listening Session Summary

March 25, 2021

Glycogen Storage Disease (GSD) Type 1B

Patient Listening Session

Patient Listening Session Summary

March 3, 2022

Gorlin Syndrome (GS)

Patient Listening Session

Patient Listening Session Summary

November 9, 2020

Gorlin Syndrome (GS)

EL-PFDD Meeting
Host: Gorlin Syndrome Alliance

Meeting Report

October 8, 2021

Guillain-Barre’ Syndrome (GBS)

Patient Listening Session

Patient Listening Session Summary

September 29, 2020

Healthcare Challenges and Unmet Medical Needs of Transgender Adults

Patient Listening Session

Patient Listening Session Summary

June 1, 2021

Healthcare Challenges and Unmet Medical Needs of Transgender Adolescents

Patient Listening Session

Patient Listening Session Summary

June 29, 2021

Hemophilia A, Hemophilia B, von Willebrand Disease (VWB), and Other Heritable Bleeding Disorders

FDA-led PFDD Meeting

 

September 22, 2014

Hepatitis B

EL-PFDD Meeting
Host: Hepatitis B Foundation

Meeting Report

June 9, 2020

Hereditary Angioedema (HAE)

FDA-led PFDD Meeting

 

September 25, 2017

Homocystinuria (HCU)

Patient Listening Session

Patient Listening Session Summary

June 26, 2020

Human Immunodeficiency Virus (HIV)

FDA-led PFDD Meeting

June 14, 2013

Hunter Syndrome (MPS II)

Patient Listening Session

Patient Listening Session Summary

February 4, 2020

Hunter Syndrome (MPS II)

N/A

Toileting Ability Survey Report

N/A

Huntington’s Disease (HD)

FDA-led PFDD Meeting

 

September 22, 2015

Hypereosinophilic Syndromes (HES)

EL-PFDD Meeting
Host: American Partnership for Eosinophilic Disorders

Meeting Report

March 23, 2018

Hyperhidrosis (Hh)

EL-PFDD Meeting
Host: International Hyperhidrosis Society

Meeting Report

November 13, 2017

Hypertrophic Cardiomyopathy (HCM)

EL-PFDD Meeting
Host: Hypertrophic Cardiomyopathy Association

Meeting Report

June 26, 2020

Hypomyelination with Atrophy of Basal Ganglia and Cerebellum (H-ABC)

Patient Listening Session

Patient Listening Session Summary

May 9, 2022

Hypophosphatemia

EL-PFDD Meeting
Host: XLH Network

Meeting Report

October 5, 2018

Hypothalamic Obesity (HO)

Patient Listening Session

Patient Listening Session Summary

October 22, 2021

Ichthyosis

Patient Listening Session

Patient Listening Session Summary

September 17, 2021

Idiopathic Pulmonary Fibrosis (IPF)

FDA-led PFDD Meeting

 

September 26, 2014

IgA Nephropathy (IgAN)

EL-PFDD Meeting
Host: National Kidney Foundation and the IgA Nephropathy Foundation of America

Meeting Report

August 19, 2019

Immune Thrombocytopenia (ITP)

EL-PFDD Meeting
Host: Platelet Disorder Support Association

Meeting Report

July 26, 2019

Inborn Errors of Metabolism (IEM)

FDA-led PFDD Meeting

 

June 10, 2014

Inclusion Body Myositis (IBM)

Patient Listening Session

Patient Listening Session Summary

March 5, 2020

Krabbe Disease

EL-PFDD Meeting
Host: National Organization for Rare Disorders (NORD)

Meeting Report

October 29, 2020

Late Onset GM2 gangliosidoses (Tay-Sachs and Sandhoff Diseases)

Patient Listening Session

Patient Listening Session Summary

January 15, 2021

Limb-Girdle Muscular Dystrophies (LGMD)

Patient Listening Session

Patient Listening Session Summary

October 20, 2020

Lung Cancer

FDA-led PFDD Meeting

 

June 28, 2013

Lupus – Diversity in Clinical Trials

Patient Listening Session

March 31, 2021 – Session 1

April 2, 2021 – Session 2

April 6, 2021 – Session 3

Lupus

EL-PFDD Meeting
Host: Lupus and Allied Diseases Association, Lupus Foundation of America, and the Lupus Research Alliance

Meeting Report

September 25, 2017

Major Depressive Disorder (MDD)

EL-PFDD Meeting
Host: Depression and Bipolar Support Alliance

Meeting Report

November 16, 2018

Mastocytosis

Patient Listening Session

Patient Listening Session Summary

September 28, 2021

Mitochondrial Disease

EL-PFDD Meeting
Host: United Mitochondrial Disease Foundation

Meeting Report

March 29, 2019

Myeloproliferative Neoplasms (MPNs)

EL-PFDD Meeting
Host: MPN Research Foundation

Meeting Report

September 16, 2019

Myotonic Dystrophy (DM)

EL-PFDD Meeting
Host: Myotonic Dystrophy Foundation

Meeting Report

September 15, 2016

Narcolepsy

FDA-led PFDD Meeting

 

September 24, 2013

Neurofibromatosis (NF)

Patient Listening Session

Patient Listening Session Summary

June 13, 2019

Neuronopathic Gaucher Disease (nGD) (Types 2 & 3)

Patient Listening Session

Patient Listening Session Summary

September 9, 2021

Neuropathic Pain Associated with Peripheral Neuropathy

FDA-led PFDD Meeting

 

June 10, 2016

Niemann-Pick Type C (NPC)

EL-PFDD Meeting
Host: Ara Parseghian Medical Research Fund at Notre Dame, Hide & Seek Foundation, Dana's Angels Research Trust, Hope for Marian, National Niemann-Pick Disease Foundation, Niemann-Pick Canada, Firefly Fund, and Johnathon's Dreams

Meeting Report

March 18, 2019

Nonalcoholic Steatohepatitis (NASH)

EL-PFDD Meeting
Host: Global Liver Institute

Meeting Report

November 4, 2021

Non-Tuberculous Mycobacterial (NTM) Lung Infections

FDA-led PFDD Meeting

 

October 15, 2015

Obstructive Sleep Apnea (OSA)

EL-PFDD Meeting
Host: American Sleep Apnea Association

Meeting Report

June 8, 2018

Ocular Melanoma (OM)

Patient Listening Session

Patient Listening Session Summary

January 27, 2020

Opioid Use Disorder (OUD)

FDA-led PFDD Meeting

The audio recording of this meeting is publicly available using the links below. Because of the sensitive nature of the meeting topic, and the importance of gathering candid, meaningful input from individuals who have come forward to speak about living with opioid use disorder, there is no video recording of the meeting.

 

April 17, 2018

Osteoarthritis (OA)

Patient Listening Session

Patient Listening Session Summary

August 7, 2019

Osteoarthritis (OA)

EL-PFDD Meeting
Host: Arthritis Foundation

Meeting Report

March 8, 2017

Osteogenesis Imperfecta (OI)

Patient Listening Session

Patient Listening Session Summary

September 17, 2019

Pachyonychia Congenita (PC)

EL-PFDD Meeting
Host: Pachyonychia Congenita Project

Meeting Report

April 6, 2018

Pancreatitis

EL-PFDD Meeting
Host: National Pancreas Foundation and FCS Foundation

Meeting Report

March 3, 2020

Parkinson’s Disease

FDA-led PFDD Meeting

 

September 22, 2015

Patients Who Have Received an Organ Transplant

FDA-led PFDD Meeting

 

September 27, 2016

Pemphigus and Pemphigoid

Patient Listening Session

Patient Listening Session Summary

February 8, 2021

Polyglutamine Spinocerebellar Ataxias (SCAs) and Dentatorubal-Pallidoluysian Atrophy (DRPLA)

EL-PFDD Meeting
Host: National Ataxia Foundation and CureDRPLA

Meeting Report

September 25, 2020

Pompe Disease

EL-PFDD Meeting
Host: Muscular Dystrophy Association

Meeting Report

July 13, 2020

Primary Sclerosing Cholangitis (PSC)

EL-PFDD Meeting
Host: PSC Partners Seeking a Cure

Meeting Report

October 23, 2020

Progressive Multifocal Leukoencephalopathy (PML)

Patient Listening Session

July 22, 2020 – Session 1

September 11, 2020 – Session 2

Psoriasis

FDA-led PFDD Meeting

 

March 17, 2016

Pulmonary Arterial Hypertension (PAH)

FDA-led PFDD Meeting

 

May 13, 2014

Pulmonary Sarcoidosis

Patient Listening Session

Patient Listening Session Summary

April 21, 2022

Pyruvate Kinase Deficiency

EL-PFDD Meeting
Host: National Organization for Rare Disorders (NORD)

Meeting Report

September 20, 2019

Sanfilippo Syndrome

Patient Listening Session

Patient Listening Session Summary

May 13, 2019

Sanfilippo Syndrome – Pediatric

Patient Listening Session

Patient Listening Session Summary

October 17, 2019

Sarcopenia

FDA-led PFDD Meeting

 

April 6, 2017

SCN2A Related Disorders

Patient Listening Session

Patient Listening Session Summary

April 28, 2021

Sensorineural Hearing Loss (SNHL)

EL-PFDD Meeting
Host: Hearing Loss Association of America

Meeting Report

May 25, 2021

Sickle Cell Disease

FDA-led PFDD Meeting

 

February 7, 2014

Smith-Magenis Syndrome (SMS)

Patient Listening Session

Patient Listening Session Summary

August 12, 2020

Spinal Muscular Atrophy (SMA)

EL-PFDD Meeting
Host: Cure SMA

Meeting Report

April 18, 2017

Stimulant Use Disorder

FDA-led PFDD Meeting

 

October 6, 2020

Systemic Sclerosis

FDA-led PFDD Meeting

 

October 13, 2020

Thymidine Kinase 2 Deficiency (TK2)

Patient Listening Session

Patient Listening Session Summary

January 31, 2022

Tuberous Sclerosis Complex (TSC)

EL-PFDD Meeting
Host: Tuberous Sclerosis Alliance

Meeting Report

June 21, 2017

Valosin Containing Protein Disease (VCP)

Patient Listening Session

Patient Listening Session Summary

May 5, 2020

Vascular Ehlers-Danlos Syndrome (VEDS)

Patient Listening Session

Patient Listening Session Summary

October 7, 2020

Vitiligo

FDA-led PFDD Meeting

 

March 8, 2021

Von Hippel Lindau (VHL)

Patient Listening Session

Patient Listening Session Summary

June 11, 2020

Xerostomia

EL-PFDD Meeting
Host: Head and Neck Cancer Alliance (HNCA), the National Foundation of Swallowing Disorders (NFOSD), Support for People with Oral and Head and Neck Cancer (SPOHNC), and the THANC (Thyroid, Head and Neck Cancer) Foundation

Meeting Report

August 19, 2021

To contact FDA’s CDER Patient-Focused Drug Development Program Staff, please email patientfocused@fda.hhs.gov.

To get updates about CDER's Patient-Focused Drug Development programs, subscribe to our free email subscription service using the button at the top of the page.

Back to CDER Patient-Focused Drug Development Homepage

 

Back to Top